IL110350A - Medical combination of the parathyroid hormone and relaxoxin to freeze bone mass - Google Patents
Medical combination of the parathyroid hormone and relaxoxin to freeze bone massInfo
- Publication number
- IL110350A IL110350A IL11035094A IL11035094A IL110350A IL 110350 A IL110350 A IL 110350A IL 11035094 A IL11035094 A IL 11035094A IL 11035094 A IL11035094 A IL 11035094A IL 110350 A IL110350 A IL 110350A
- Authority
- IL
- Israel
- Prior art keywords
- raloxifene
- parathyroid hormone
- pth
- bone
- bone mass
- Prior art date
Links
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 229960004622 raloxifene Drugs 0.000 title claims abstract description 61
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 40
- 102000003982 Parathyroid hormone Human genes 0.000 title claims description 58
- 108090000445 Parathyroid hormone Proteins 0.000 title claims description 58
- 229960001319 parathyroid hormone Drugs 0.000 title claims description 58
- 239000000199 parathyroid hormone Substances 0.000 title claims description 58
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 206010065687 Bone loss Diseases 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims description 11
- 238000002648 combination therapy Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000011970 concomitant therapy Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 8
- 241000700159 Rattus Species 0.000 description 15
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 239000007943 implant Substances 0.000 description 9
- 210000000689 upper leg Anatomy 0.000 description 9
- 230000008468 bone growth Effects 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 7
- 230000037396 body weight Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 4
- 239000000501 collagen implant Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 208000005368 osteomalacia Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9648093A | 1993-07-22 | 1993-07-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL110350A0 IL110350A0 (en) | 1994-10-21 |
| IL110350A true IL110350A (en) | 2002-02-10 |
Family
ID=22257534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11035094A IL110350A (en) | 1993-07-22 | 1994-07-18 | Medical combination of the parathyroid hormone and relaxoxin to freeze bone mass |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US5510370A (pt) |
| EP (1) | EP0635270B1 (pt) |
| JP (1) | JPH0769920A (pt) |
| KR (1) | KR100306852B1 (pt) |
| CN (1) | CN1105577C (pt) |
| AT (1) | ATE189959T1 (pt) |
| AU (1) | AU686628B2 (pt) |
| BR (1) | BR9402902A (pt) |
| CA (1) | CA2128376A1 (pt) |
| CY (1) | CY2192B1 (pt) |
| CZ (1) | CZ289648B6 (pt) |
| DE (1) | DE69423146T2 (pt) |
| DK (1) | DK0635270T3 (pt) |
| ES (1) | ES2142380T3 (pt) |
| GR (1) | GR3033492T3 (pt) |
| HK (1) | HK1013800A1 (pt) |
| HU (1) | HU219382B (pt) |
| IL (1) | IL110350A (pt) |
| MY (1) | MY124311A (pt) |
| NO (1) | NO942708L (pt) |
| NZ (2) | NZ280040A (pt) |
| PE (1) | PE14595A1 (pt) |
| PH (1) | PH30686A (pt) |
| PL (1) | PL304348A1 (pt) |
| PT (1) | PT635270E (pt) |
| RU (1) | RU2155042C2 (pt) |
| SI (1) | SI0635270T1 (pt) |
| TW (1) | TW303299B (pt) |
| YU (1) | YU49170B (pt) |
| ZA (1) | ZA945249B (pt) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| USRE39049E1 (en) | 1992-07-28 | 2006-03-28 | Eli Lilly And Company | Methods for inhibiting bone loss |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| USRE38968E1 (en) | 1992-07-28 | 2006-02-07 | Eli Lilly And Company | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride |
| US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US6395494B1 (en) | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
| US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6319914B1 (en) | 1993-11-05 | 2001-11-20 | Apollo Biopharmaceuticals, Inc. | Cytoprotective effect of polycyclic phenolic compounds |
| US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
| US6417198B1 (en) | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
| US5578613A (en) * | 1993-12-21 | 1996-11-26 | Eli Lilly And Company | Methods for inhibiting weight gain or inducing weight loss |
| US5972383A (en) * | 1994-03-02 | 1999-10-26 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
| US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
| US5811120A (en) * | 1994-03-02 | 1998-09-22 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
| US5502074A (en) * | 1994-08-22 | 1996-03-26 | Eli Lilly And Company | Benzothiophenes for bone healing and fracture repair |
| CA2199250A1 (en) * | 1994-09-09 | 1996-03-14 | John Althorp Bevan | Estrogens and parathyroid hormone for treating osteoporosis |
| US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| KR19980701933A (ko) * | 1995-02-06 | 1998-06-25 | 피터 쥐. 스트링거 | 인터루킨-6의 작용의 억제 방법 |
| AU6277396A (en) * | 1995-06-07 | 1996-12-30 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
| JP3263598B2 (ja) * | 1995-11-01 | 2002-03-04 | 有限会社ドット | 経鼻吸収用生理活性ペプチド組成物 |
| AU761274B2 (en) * | 1996-01-29 | 2003-05-29 | Schering Aktiengesellschaft | Pharmaceutical combination preparation that consists of LHRH-analogues and antiestrogens for treating gynecological disorders |
| IL120270A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| WO1999004808A1 (fr) * | 1997-07-22 | 1999-02-04 | Chugai Seiyaku Kabushiki Kaisha | Medicaments dentaires contenant de la pth |
| AU9682098A (en) * | 1997-10-14 | 1999-05-03 | Eli Lilly And Company | Method of building and maintaining bone |
| US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| US20040176470A1 (en) * | 1998-05-07 | 2004-09-09 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
| US20040033950A1 (en) * | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
| EP1119251A4 (en) * | 1998-10-07 | 2004-03-24 | Univ Arkansas | METHOD FOR SCREENING ON ANALOG BONE THERAPY ACTIVE SUBSTANCES THAT CONTROL APOPTOSIS AND THEIR USE |
| WO2000028982A2 (en) | 1998-11-19 | 2000-05-25 | The Board Of Trustees For The University Of Arkansas | Increasing bone strength with selected bisphosphonates |
| US20040214889A1 (en) * | 1999-07-31 | 2004-10-28 | Smithkline Beecham Corporation | Calcilytic compounds |
| WO2001022093A1 (en) * | 1999-09-20 | 2001-03-29 | Eli Lilly And Company | Method for monitoring treatment with a parathyroid hormone |
| EP1339312B1 (en) * | 2000-10-10 | 2006-01-04 | Microchips, Inc. | Microchip reservoir devices using wireless transmission of power and data |
| US20030216358A1 (en) * | 2001-07-05 | 2003-11-20 | Muchmore Douglas Boyer | Method for enhancing bone mineral density gain |
| ES2319785T3 (es) * | 2001-11-29 | 2009-05-12 | Gtx, Inc. | Prevencion y tratamiento de osteoporosis inducida por privacion de androgenos. |
| US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
| US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
| US20050080143A1 (en) * | 2001-11-29 | 2005-04-14 | Steiner Mitchell S. | Treatment of androgen-deprivation induced osteoporosis |
| US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
| US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
| US7247609B2 (en) * | 2001-12-18 | 2007-07-24 | Universitat Zurich | Growth factor modified protein matrices for tissue engineering |
| CN1658868A (zh) * | 2002-06-13 | 2005-08-24 | 惠氏公司 | 巴泽昔芬治疗方案 |
| JP3887588B2 (ja) * | 2002-08-30 | 2007-02-28 | 株式会社リガク | Ｘ線回折による応力測定法 |
| WO2004022033A1 (en) * | 2002-09-04 | 2004-03-18 | Microchips, Inc. | Method and device for the controlled delivery of parathyroid hormone |
| US8273347B2 (en) | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
| US7553827B2 (en) * | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
| US20040229878A1 (en) * | 2003-05-13 | 2004-11-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of P38 kinase |
| US7429378B2 (en) * | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
| US7344716B2 (en) * | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
| US20060106010A1 (en) * | 2003-05-27 | 2006-05-18 | Black Larry J | Methods for inhibiting bone loss |
| US8361467B2 (en) * | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
| US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| KR20060127875A (ko) * | 2004-01-13 | 2006-12-13 | 와이어쓰 | 아로마타제 억제제 요법-관련된 골다공증의 치료 |
| JP5007427B2 (ja) * | 2004-05-13 | 2012-08-22 | アルザ コーポレイション | 副甲状腺ホルモン剤の経皮送達のための装置および方法 |
| US7648965B2 (en) * | 2004-05-14 | 2010-01-19 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| US7531518B2 (en) * | 2004-05-14 | 2009-05-12 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
| WO2006073711A2 (en) * | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Use of a matrix comprising a contrast agent in soft tissues |
| WO2006081279A2 (en) * | 2005-01-25 | 2006-08-03 | Microchips, Inc. | Control of drug release by transient modification of local microenvironments |
| US20080076975A1 (en) * | 2005-01-25 | 2008-03-27 | Microchips, Inc. | Method and implantable device with reservoir array for pre-clinical in vivo testing |
| US20060293667A1 (en) * | 2005-05-19 | 2006-12-28 | Agnes Vignery | Bone implant device and methods of using same |
| US7691105B2 (en) * | 2005-09-26 | 2010-04-06 | Depuy Spine, Inc. | Tissue augmentation, stabilization and regeneration technique |
| US20070088436A1 (en) * | 2005-09-29 | 2007-04-19 | Matthew Parsons | Methods and devices for stenting or tamping a fractured vertebral body |
| US20070173447A1 (en) * | 2005-10-25 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent |
| CA2628945A1 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US20070168041A1 (en) * | 2006-01-17 | 2007-07-19 | Sudhakar Kadiyala | Method and instruments for intervertebral disc augmentation through a pedicular approach |
| SI3345607T1 (sl) | 2006-12-29 | 2023-03-31 | Ossifi-Mab Llc | Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE |
| ES2381639T3 (es) * | 2007-04-13 | 2012-05-30 | Kuros Biosurgery Ag | Sellante polimérico para tejidos |
| US8241363B2 (en) | 2007-12-19 | 2012-08-14 | Depuy Spine, Inc. | Expandable corpectomy spinal fusion cage |
| US8241294B2 (en) * | 2007-12-19 | 2012-08-14 | Depuy Spine, Inc. | Instruments for expandable corpectomy spinal fusion cage |
| US8986696B2 (en) * | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
| US20090162351A1 (en) * | 2007-12-21 | 2009-06-25 | Depuy Spine, Inc. | Transdiscal administration of inhibitors of p38 MAP kinase |
| US8876905B2 (en) * | 2009-04-29 | 2014-11-04 | DePuy Synthes Products, LLC | Minimally invasive corpectomy cage and instrument |
| AU2009356227A1 (en) | 2009-12-07 | 2012-06-21 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US20130138221A1 (en) * | 2010-04-16 | 2013-05-30 | Novartis Ag | Methods and compositions for improving implant osseointegration |
| ES2882852T3 (es) | 2011-03-16 | 2021-12-02 | Kuros Biosurgery Ag | Formulación farmacéutica para la utilización en la fusión espinal |
| WO2015187994A1 (en) * | 2014-06-04 | 2015-12-10 | Cedars-Sinai Medical Center | Method for non surgical repair of vertebral compression fractures |
| GB2590692A (en) * | 2019-12-24 | 2021-07-07 | Corthotec Ltd | Composition for improved bone fracture healing |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| IL78342A (en) * | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
| US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
-
1993
- 1993-08-02 TW TW082106163A patent/TW303299B/zh active
-
1994
- 1994-07-18 DK DK94305238T patent/DK0635270T3/da active
- 1994-07-18 AT AT94305238T patent/ATE189959T1/de not_active IP Right Cessation
- 1994-07-18 PE PE1994246921A patent/PE14595A1/es not_active Application Discontinuation
- 1994-07-18 IL IL11035094A patent/IL110350A/en not_active IP Right Cessation
- 1994-07-18 NZ NZ280040A patent/NZ280040A/en unknown
- 1994-07-18 ZA ZA945249A patent/ZA945249B/xx unknown
- 1994-07-18 DE DE69423146T patent/DE69423146T2/de not_active Expired - Fee Related
- 1994-07-18 EP EP94305238A patent/EP0635270B1/en not_active Expired - Lifetime
- 1994-07-18 SI SI9430323T patent/SI0635270T1/xx unknown
- 1994-07-18 ES ES94305238T patent/ES2142380T3/es not_active Expired - Lifetime
- 1994-07-18 PT PT94305238T patent/PT635270E/pt unknown
- 1994-07-18 NZ NZ264027A patent/NZ264027A/en unknown
- 1994-07-18 CZ CZ19941733A patent/CZ289648B6/cs not_active IP Right Cessation
- 1994-07-19 AU AU67577/94A patent/AU686628B2/en not_active Ceased
- 1994-07-19 NO NO942708A patent/NO942708L/no not_active Application Discontinuation
- 1994-07-19 CA CA002128376A patent/CA2128376A1/en not_active Abandoned
- 1994-07-19 PL PL94304348A patent/PL304348A1/xx unknown
- 1994-07-19 RU RU94027680/14A patent/RU2155042C2/ru not_active IP Right Cessation
- 1994-07-19 JP JP6166809A patent/JPH0769920A/ja active Pending
- 1994-07-20 PH PH48671A patent/PH30686A/en unknown
- 1994-07-20 KR KR1019940017456A patent/KR100306852B1/ko not_active IP Right Cessation
- 1994-07-21 HU HU9402157A patent/HU219382B/hu not_active IP Right Cessation
- 1994-07-21 BR BR9402902A patent/BR9402902A/pt not_active Application Discontinuation
- 1994-07-21 YU YU46794A patent/YU49170B/sh unknown
- 1994-07-21 CN CN94108159A patent/CN1105577C/zh not_active Expired - Fee Related
- 1994-07-22 MY MYPI94001920A patent/MY124311A/en unknown
-
1995
- 1995-03-06 US US08/400,436 patent/US5510370A/en not_active Expired - Fee Related
-
1998
- 1998-12-23 HK HK98115198A patent/HK1013800A1/xx not_active IP Right Cessation
-
2000
- 2000-05-24 GR GR20000401189T patent/GR3033492T3/el not_active IP Right Cessation
- 2000-08-02 CY CY0000034A patent/CY2192B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0635270B1 (en) | Parathyroid hormone and raloxifene for increasing bone mass | |
| EP0756483B1 (en) | Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis | |
| US5118667A (en) | Bone growth factors and inhibitors of bone resorption for promoting bone formation | |
| JP3053116B2 (ja) | 医薬組成物 | |
| CA2151240A1 (en) | Biophosphonate/estrogen therapy for treating and preventing bone loss | |
| PL195703B1 (pl) | Zastosowanie polipeptydowego analogu peptydu pokrewnego hormonowi przytarczyc | |
| US5861438A (en) | Combination therapy to prevent bone loss parathyroid hormone and estrogen agonists | |
| US6399592B1 (en) | Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss | |
| Wittbjer et al. | Bone formation in demineralized bone transplants treated with biosynthetic human growth hormone | |
| MXPA96004968A (en) | Use of bisphosphonates to inhibit bone rebassion after the implantation of orthopedic protesis | |
| MXPA97001526A (en) | Combined therapy to treat osteoporo | |
| AU2005203308A1 (en) | Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis | |
| AU9745901A (en) | Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |